tradingkey.logo
tradingkey.logo

Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial

ReutersJul 31, 2025 12:22 PM

- Pasithea Therapeutics Corp KTTA.O:

  • PASITHEA THERAPEUTICS COMPLETES ENROLLMENT AND INITIAL DOSING OF FIRST COHORT FROM ITS PHASE 1/1B CLINICAL TRIAL OF PAS-004 IN ADULT NF1 PATIENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI